01/24/2025
3:44 PM | Agarwal Arjun (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2025
3:41 PM | Klein Lawrence Otto (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2025
3:42 PM | Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Quinlan Paul T (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/24/2025
3:43 PM | Goncalves Joana (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/19/2024
6:16 AM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/26/2024
11:15 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form EFFECT | |
11/21/2024
5:30 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/21/2024
5:30 PM | Fairmount Funds Management LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D/A | |
11/14/2024
6:38 PM | Avidity Partners Management LP (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
4:49 PM | Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
4:20 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
|
11/14/2024
3:56 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
11:04 AM | Allostery Investments LP (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:56 AM | JANUS HENDERSON GROUP PLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
5:37 AM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
11/13/2024
3:01 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/22/2024
3:15 PM | Adage Capital Management, L.P. (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D/A | |
10/18/2024
3:11 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form DEF 14A | |
10/07/2024
10:37 AM | FMR LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G | |
10/04/2024
3:05 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/13/2024
3:55 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/13/2024
3:57 PM | Fairmount Funds Management LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D/A | |
09/06/2024
4:00 PM | Klein Lawrence Otto (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:01 PM | Agarwal Arjun (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:02 PM | Goncalves Joana (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:03 PM | Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Quinlan Paul T (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:04 PM | BALL KRISTINE M (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:05 PM | Dambkowski Carl (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:06 PM | Kulkarni Samarth (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:07 PM | Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Turtle Cameron (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:07 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Co-Invest III L.P. (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Oruka Therapeutics, Inc. (Issuer)
Oruka Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
09/06/2024
4:08 PM | Fairmount Funds Management LLC (Filed by)
Oruka Therapeutics, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13D | |
09/05/2024
4:18 PM | Oruka Therapeutics, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/30/2024
4:57 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Ma-Weaver Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/26/2024
6:51 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/26/2024
6:53 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/23/2024
3:35 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/20/2024
1:23 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/16/2024
3:25 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/16/2024
3:27 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/15/2024
3:15 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Is this the pin that pops the bubble? (Ad) CEO Jensen Huang does not want you knowing this dirty little secret about Nvidia…
In fact, any day now we’re expecting a cease and desist from Nvidia’s lawyers.
Go here now before it’s too late to find out why Nvidia shares are slumping so hard. Go Here Now Before It’s Too Late |
08/15/2024
3:17 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/09/2024
7:35 AM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
08/01/2024
3:30 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
07/26/2024
9:50 AM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/24/2024
11:15 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form EFFECT | |
07/24/2024
3:49 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form ARS | |
07/22/2024
4:17 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4/A | |
07/12/2024
6:38 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
6:10 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Janus Henderson Biotech Innovation Master Fund Ltd (Reporting)
JANUS HENDERSON GROUP PLC (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
07/09/2024
4:29 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4/A | |
07/09/2024
4:01 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/09/2024
4:04 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
07/05/2024
4:20 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
06/18/2024
4:17 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4/A | |
06/06/2024
3:45 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
05/13/2024
8:11 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form S-4
Registration statement under Securities Act of 1933 | |
04/29/2024
6:28 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G | |
04/25/2024
3:27 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
04/23/2024
3:20 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/15/2024
4:29 PM | Allostery Investments LP (Filed by)
ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form SC 13G | |
04/11/2024
8:51 AM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G | |
04/09/2024
7:57 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
Avidity Partners Management LP (Filed by)
| Form SC 13G | |
04/05/2024
6:38 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
Western Standard LLC (Filed by)
| Form SC 13G/A | |
04/03/2024
6:31 AM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/03/2024
6:33 AM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
| Form 425 | |
02/07/2024
12:08 PM | ARCA biopharma, Inc. (Subject)
Oruka Therapeutics (Subject)
BML Investment Partners, L.P. (Filed by)
| Form SC 13G/A | |
02/01/2024
3:39 PM | ARCA biopharma, Inc. (Filer)
Oruka Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/31/2024
5:39 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Ma-Weaver Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Woosley Raymond L. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Grais Linda (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
CONWAY ROBERT E (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Flynn James P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
MITCHELL DANIEL J (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/31/2024
3:25 PM | ARCA biopharma, Inc. (Issuer)
Oruka Therapeutics (Issuer)
Hove Anders D (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
